Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Radiotherapy & Radiosurgery
Lutetium-177 therapy
What lutetium-177 therapy is, how targeted beta radiation binds to PSMA and neuroendocrine receptors, what clinical trials say about survival and symptom control, approximate costs in Turkey compared with the UK, US and Germany, who qualifies, cycle timelines, radiation safety at home, realistic scan results and how to choose an accredited nuclear medicine department.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Radiotherapy & Radiosurgery
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Lutetium-177 Therapy
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
Lutetium-177 therapy in Turkey: what it is and how it works
Lutetium-177 therapy (also known as 177Lu radioligand therapy or peptide receptor radionuclide therapy) is an advanced targeted internal radiation treatment for progressive, metastatic cancers. Unlike external radiation that passes through the skin, this therapy uses a radioactive isotope bound to a targeting molecule. The compound circulates through the bloodstream, binds specifically to receptors on cancer cells, and delivers localized beta radiation that destroys malignant cells while sparing nearby healthy tissue. Hospitals in Turkey offer this treatment within specialized nuclear medicine departments for conditions including metastatic prostate cancer and neuroendocrine tumours. For related options, see our overview of oncology treatments in Turkey.
Because the therapeutic range of beta radiation emitted by lutetium-177 is under two millimetres, damage to surrounding normal organs is limited compared with traditional chemotherapy. Lutetium-177 therapy is not for early-stage localized cancer; it is designed for advanced disease that has progressed despite standard therapies. This guide covers how it works, clinical trial evidence, approximate costs in Turkey against the UK, US and Germany, eligibility, recovery and how to choose an accredited centre.
How does lutetium-177 target cancer cells?
The mechanism relies on theranostics, which combines diagnostic imaging with targeted therapy. Certain cancer cells overexpress specific surface proteins: prostate cancer cells express prostate-specific membrane antigen (PSMA), while neuroendocrine tumour cells express somatostatin receptors. Chemists attach a matching ligand to seek out these exact receptor sites.
First, a diagnostic PET/CT scan using a tracer such as gallium-68 (68Ga) PSMA or DOTATATE confirms that tumours absorb the compound avidly. Once confirmed, the therapeutic isotope lutetium-177 is attached to the same ligand. After intravenous infusion, the molecule binds to tumorous receptors and is drawn into the malignant cell. As lutetium-177 decays with a 6.6-day half-life, it emits short-range beta particles that cause double-strand DNA breaks in the cancer cells, halting replication.
Does lutetium-177 therapy work? Evidence and clinical trials
International clinical trials demonstrate clear efficacy for lutetium-177 therapy in specific advanced cancers. In metastatic castration-resistant prostate cancer, the phase III VISION trial evaluated 177Lu-PSMA-617 in patients previously treated with chemotherapy and androgen receptor pathway inhibitors. The study demonstrated statistically significant improvements in overall survival and progression-free survival, alongside notable reductions in PSA levels and bone pain relief.
For neuroendocrine tumours, the phase III NETTER-1 trial showed that 177Lu-DOTATATE (Lutathera) markedly prolonged progression-free survival compared with standard high-dose octreotide, leading to approval by the US FDA and European Medicines Agency (EMA). However, lutetium-177 therapy is a disease-controlling palliative treatment, not a cure for terminal cancer. Tumours without sufficient target receptors will not respond, and resistance can develop over time. A trustworthy oncology team will explain these boundaries clearly.
Lutetium-177 therapy cost in Turkey compared with the UK, US and Germany
The figures below are approximate cost ranges per cycle, not hospital quotes. Total cost depends on how many cycles are needed (typically four to six), diagnostic imaging, inpatient isolation and medical monitoring. Each hospital confirms pricing in a written quote.
| Country | Approximate cost range per cycle |
|---|---|
| Turkey | €3,500 – €7,500 |
| United Kingdom | €9,000 – €18,000 |
| United States | €18,000 – €35,000 |
| Germany | €8,500 – €16,000 |
What influences the lutetium-177 therapy price: the custom synthesis and transport of the isotope due to its 6.6-day half-life, diagnostic 68Ga-PSMA or DOTATATE PET/CT scans, kidney-protecting infusions and the length of inpatient isolation in a lead-lined room. A standard package covers the radiopharmaceutical dose, pre-medication, one to two nights in isolation, nursing care, radiation safety monitoring and post-therapy scintigraphy.
Lutetium-177 therapy compared with tomotherapy, gamma knife and chemotherapy
Patients often compare targeted radionuclide therapy with other oncology treatments. While external radiation treats localized areas, lutetium-177 circulates systemically to reach widespread lesions.
| Treatment approach | Best suited to | Typical limits |
|---|---|---|
| Lutetium-177 therapy | Widespread metastases expressing PSMA or somatostatin receptors | Ineffective if tumours lack receptors; requires adequate marrow and kidney reserve |
| Tomotherapy | Complex regional tumours requiring modulated external beam radiation | Limited to mapped anatomical fields; cannot treat unmapped microscopic spread |
| Gamma Knife | Small, well-defined intracranial brain lesions and metastases | Confined strictly to the brain; does not treat extracranial systemic disease |
| Systemic chemotherapy | Broad cytotoxic destruction of rapidly dividing malignant cells | Non-targeted systemic side effects including hair loss and immune suppression |
These approaches can be complementary. For example, focused external radiation such as tomotherapy or stereotactic treatment with gamma knife can treat an isolated painful spinal or brain lesion, while lutetium-177 addresses micro-metastases throughout the bones and organs.
Who is a candidate for lutetium-177, and who is not?
Suitability depends on precise molecular and clinical criteria. Good candidates generally include:
- Adults with progressive metastatic prostate cancer or advanced neuroendocrine tumours that have progressed after standard therapies.
- Patients whose pre-treatment 68Ga PET/CT scan demonstrates high receptor avidity across all known tumorous lesions.
- Individuals with adequate bone marrow function (acceptable red blood cell, white blood cell and platelet counts).
- Patients with sufficient kidney function (creatinine clearance or eGFR above 30 to 50 mL/min) and liver function.
- Those with reasonable general strength (ECOG performance status 0 to 2) to manage travel and mild recovery.
Poor candidates include patients whose tumours lack target receptor expression, or those with discordant disease where non-avid tumours are growing. Severe kidney failure, unmanageable bone marrow suppression, active serious infections, unrelieved urinary obstruction and pregnancy or breastfeeding are strict contraindications.
The treatment session step by step: from infusion to discharge
A treatment cycle follows a structured sequence in a licensed nuclear medicine facility to ensure efficacy and radiation safety.
On admission, the medical team conducts blood tests to verify kidney and marrow function. An intravenous line is placed. For neuroendocrine tumour treatments, an amino acid infusion (lysine and arginine) begins 30 to 60 minutes before the isotope to protect the kidneys from reabsorbing radiation. Patients also receive anti-nausea medication.
The lutetium-177 solution is infused intravenously through a lead-shielded line over 15 to 30 minutes. Following administration, the patient stays in a private, lead-lined isolation room for 24 to 48 hours. Specialized nurses monitor vitals while fluids are encouraged to promote urinary clearance. Once external radiation drops below statutory discharge levels, a post-treatment SPECT/CT scan verifies tumour uptake before the patient is discharged.
Lutetium-177 therapy recovery and radiation safety at home
Patients travelling to Turkey generally stay four to six days per cycle for pre-treatment tests, infusion, isolation and radiation clearance checks. Most plans involve four to six cycles administered six to eight weeks apart.
Physical recovery is usually mild, with fatigue and slight nausea easing within two to four days. Because residual radiation clears through bodily fluids, patients follow home radiation precautions for three to seven days:
- Sleep in a separate bed at least two metres away from partners.
- Avoid prolonged close contact with pregnant women and children under eighteen.
- Use a separate toilet where possible, flush twice with the lid down, and sit while urinating.
- Wash hands thoroughly, and wash personal clothing and towels separately.
- Drink two to three litres of water daily to assist renal excretion.
Routine blood counts and kidney tests should be performed at home at two, four and six weeks post-infusion before the next cycle.
Lutetium-177 therapy before and after: what scans and markers show
In systemic radionuclide therapy, before-and-after results are measured through imaging and blood markers rather than physical photographs. Clinical evaluation relies on three main markers: laboratory indicators, molecular imaging and symptom relief.
In prostate cancer, many patients experience a marked drop in PSA levels after two to three cycles. In neuroendocrine tumours, reductions in chromogranin A indicate treatment response. Post-treatment SPECT/CT and follow-up PET/CT scans frequently show decreased metabolic activity or disease stabilization in bone and organ metastases. Many patients report significant reductions in bone pain, improved energy and less need for pain medication.
However, scans do not show instant changes, and an early temporary rise in PSA (flare phenomenon) can occur as tumour cells break down. Stable disease on scans is regarded as a valuable clinical outcome in advanced cancer. A reputable clinic will explain what imaging shows without making false promises.
Risks and side effects of targeted radionuclide therapy
Lutetium-177 therapy typically produces fewer acute systemic side effects than conventional cytotoxic chemotherapy, but it carries recognized side effects documented by regulatory bodies including the NHS, FDA and EANM.
Common short-term effects include mild fatigue, temporary nausea and decreased appetite. With PSMA therapy, dry mouth (xerostomia) is common because salivary glands express PSMA and take up small amounts of radiation; applying ice packs to the salivary glands during infusion helps reduce this effect. Mild dry eyes may also occur.
The primary systemic concern is bone marrow suppression (myelosuppression), which can temporarily lower red blood cells, white blood cells or platelets. Blood levels are tracked between cycles to ensure recovery. Kidney toxicity is rare when protective hydration and amino acids are used. Secondary bone marrow disorders remain exceedingly rare late complications in heavily pre-treated cancer patients.
How to choose an accredited nuclear medicine centre, and red flags
When choosing a hospital in Turkey for lutetium-177 therapy, verify that the facility has a licensed nuclear medicine department staffed by board-certified nuclear medicine specialists, medical oncologists and radiation physicists. The department must feature lead-shielded isolation rooms, dedicated waste systems and on-site PET/CT and SPECT/CT scanners. Before return travel, the hospital must provide an official radiation release certificate in English.
Red flags include offering treatment without a recent receptor PET/CT scan, promising a cure, omitting isotope costs from the quote, or lacking aftercare communication. Key questions to ask:
- Does a multidisciplinary tumour board review my case before scheduling?
- Is the isotope synthesized specifically for my visit, and what happens if travel is delayed?
- What post-infusion dosimetry imaging is included to measure absorbed tumour radiation?
- How will my home oncologist receive treatment reports and monitoring schedules?
Learn how our process works to understand international care coordination, and submit your records via our free quote page for a clinical review from Turkish hospitals offering oncology treatments in Turkey.
Hospitals with Oncology in Turkey
Frequently asked questions
Lutetium-177 therapy is a targeted form of internal radiotherapy known as radioligand therapy. A radioactive isotope, lutetium-177, is linked to a targeting molecule that binds specifically to cancer cell receptors, such as PSMA in prostate cancer or somatostatin receptors in neuroendocrine tumours, delivering localized beta radiation that destroys malignant cells while preserving surrounding healthy tissue.
Major clinical trials, including the phase III VISION and NETTER-1 studies, show that lutetium-177 therapy significantly extends overall survival and slows disease progression in patients with receptor-positive metastatic prostate cancer and neuroendocrine tumours. While not curative in metastatic disease, it frequently reduces tumour size, lowers tumour markers, and alleviates pain and other debilitating cancer symptoms.
In Turkey, lutetium-177 therapy generally costs between €3,500 and €7,500 per cycle, compared with €9,000 to €18,000 in the UK and €18,000 to €35,000 in the US. Total costs depend on the number of cycles prescribed, diagnostic PET/CT scans, inpatient isolation duration, and individualized dosimetry. Clinics provide confirmed pricing in a written quotation.
Before-and-after evaluations in radionuclide therapy rely on diagnostic imaging and laboratory markers rather than cosmetic photographs. Follow-up PET/CT and SPECT scans typically demonstrate reduced metabolic activity or stabilised disease in bone and soft-tissue metastases, accompanied by declining PSA or chromogranin A levels and meaningful relief from cancer-related pain.
External radiation techniques, such as tomotherapy, deliver focused radiation beams from outside the body to defined anatomical targets. In contrast, lutetium-177 therapy travels through the bloodstream to seek out micro-metastases throughout the entire body. Radionuclide therapy is therefore suited for systemic metastatic disease, whereas external beam treatments manage localized or regional tumours.
The infusion itself is administered intravenously over 15 to 30 minutes and causes minimal discomfort, similar to receiving a standard saline drip. Some patients experience temporary mild nausea, fatigue, or abdominal discomfort during or immediately following administration, which is routinely managed with preventative anti-sickness medication.
Common side effects include mild fatigue, transient nausea, temporary dry mouth, and loss of appetite. Because beta radiation affects bone marrow, patients may experience temporary reductions in red blood cells, white blood cells, or platelets. Serious kidney impairment is uncommon when proper hydration and kidney-protecting infusions are administered.
Most patients recover from acute fatigue within three to five days of the infusion. Radiation safety precautions—such as maintaining distance from children and sleeping alone—are typically observed for three to seven days. Regular blood tests monitor bone marrow and kidney function every two to four weeks between cycles.
A typical trip to Turkey requires four to six days per cycle. This schedule allows time for pre-treatment blood tests, consultation with the nuclear medicine team, the infusion, a 24- to 48-hour inpatient isolation stay, and a pre-flight radiation survey to ensure radiation levels comply with international travel standards.
The duration of disease control varies by cancer type, receptor avidity, and prior treatments. Clinical trial data show disease progression is often delayed by several months to over a year, with many patients enjoying sustained reductions in pain and prolonged functional independence across multiple treatment cycles.
Patient stories